other material
confidence high
sentiment neutral
materiality 0.50
Glucotrack issues 406,198 new warrants at $7.50 after holders waive issuance and VRT restrictions
Glucotrack, Inc.
- Glucotrack's Oct. 13, 2026 waiver with Requisite Holders ends the 90-day equity issuance restriction and warrant variable-rate price adjustment from the July 14, 2026 purchase agreement.
- In exchange, Glucotrack will issue New Warrants for 406,198 common shares at $7.50 per share; they expire in five years and carry a 9.99% beneficial ownership cap.
- The New Warrants are not exercisable until stockholders approve the Warrant Shares under Nasdaq Listing Rule 5635; the exercise price has customary adjustments with a 20% closing-price floor.
- The equity-issuance waiver covers all Holders, while the variable-rate exercise-price waiver applies only to Existing Warrants held by Holders that signed; other transaction documents remain in force.